Studie COL-ECMO2022 a další zkušenosti s TDM kolistinu

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English The COL-ECMO2022 study and other experiences with colistin TDM
Authors

RYCHLÍČKOVÁ Jitka SUK Pavel KUBÍČKOVÁ Vendula URBÁNEK Karel

Year of publication 2023
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description With emerging antimicrobial resistance, colistin is again becoming a relevant therapeutic alternative. However, it is a drug with a narrow therapeutic window, burdened with significant inter- and intra-individual variability potentiated by the fact that colistin is administered as an inactive pro-drug that is non-enzymatically converted to the active substance. Moreover, the prodrug has completely different pharmacokinetics. Colistin is one of the antibiotics with an effect dependent on the area under the plasma concentration (AUC) curve, with the target AUC at a steady state (AUCSS, 24h) of approximately 50 mg × h/l. A reliable estimate of AUC in the context of the known high variability in both the treated patient population and the product requires frequent sampling and construction of individual curves. This report will present the concept of colistin therapeutic monitoring implemented in a pilot study and applied in the follow-up study COL-ECMO2022. The COL-ECMO study is a prospective, non-randomized, monocentric, phase IV pharmacokinetic study designed to evaluate the effect of ECMO on colistin pharmacokinetics. The study was approved by the Ethics Committee of St. Anne's Hospital in Brno. EudraCT Number: 2022- 000291-19; ClinicalTrials.gov: NCT05542446. The study started on October 1, 2022 and is currently recruiting patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.